Drugs

Nov 8, 2024, 18:35

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

Erman Akkus shared a post on X:

”Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity?

HR: 0.91 (95% CI 0.73–1.14) In patients with a history of CVD?

HR: 0.81 (95% CI 0.58–1.15)”

Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data

Authors: Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye.

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

aromatase inhibitor Bent Ejlertsen Breast Cancer cancer Denmark Erman Akkus Giulia Corn ischaemic cardiotoxicity Jan Wohlfahrt Kim Dalhoff Lars Køber Mads Melbye Maj-Britt Jensen Marie Lund OncoDaily Oncology postmenopausal patients The Lancet Oncology Tonny Petersen

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology